Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917

CS-917 (MB06322) is a selective small compound inhibitor of fructose 1,6-bisphosphatase (FBPase), which is expected to be a novel drug for the treatment of type 2 diabetes by inhibiting gluconeogenesis. CS-917 is a bisamidate prodrug and activation of CS-917 requires a two-step enzyme catalyzed reac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubota, Kazuishi, Inaba, Shin-ichi, Nakano, Rika, Watanabe, Mihoko, Sakurai, Hidetaka, Fukushima, Yumiko, Ichikawa, Kimihisa, Takahashi, Tohru, Izumi, Takashi, Shinagawa, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492754/
https://www.ncbi.nlm.nih.gov/pubmed/26171222
http://dx.doi.org/10.1002/prp2.138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492754/
https://www.ncbi.nlm.nih.gov/pubmed/26171222
http://dx.doi.org/10.1002/prp2.138

Ejemplares similares